Navigation Links
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Date:5/18/2008

- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70% - RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with potential to address

unmet medical need - Once-daily oral RAD001 directly targets and continuously inhibits mTOR, a

protein that controls tumor cell division and blood vessel growth - RAD001 is currently being studied in multiple types of cancer including

neuroendocrine, breast, gastric, lung, and lymphoma

EAST HANOVER, N.J., May 19 /PRNewswire/ -- New data show RAD001 (everolimus) may provide an important new treatment option for patients with advanced kidney cancer who have failed standard therapies.

The interim study findings demonstrated that RAD001 significantly extended the time without tumor growth from 1.9 to 4 months and reduced the risk of cancer progression by 70% (hazard ratio = 0.30 with 95% CI 0.22 to 0.40; p- value < 0.0001). The study, RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily), will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, US on Saturday, May 31, 2008.

Earlier this year, an independent data monitoring committee stopped the RECORD-1 trial after interim results showed that patients receiving RAD001 experienced a significantly longer time without their cancer worsening compared to patients receiving placebo. The trial included patients whose cancer had stopped responding to approved treatments for renal cell carcinoma (RCC), such as Nexavar(R) (sorafenib) or Sutent(R) (sunitinib), or both.

RAD001 is a once-daily oral therapy that may offer a new approach to cancer treatment by continuously inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells.

"This is the first study to show clinical benefit in patients with
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
3. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
4. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
5. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Indien, August 1, 2014 ... Inc. gaben heute bekannt, vor kurzem für ... zur Schmerzbehandlung nach chirurgischen Eingriffen eine kommerzielle ... der Europäischen Union und weiterer europäischer Länder ... und mit Ropivacain gefüllte OneDose ReadyfusOR später ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Care®, Inc. (NASDAQ: TNDM ), a medical device ... its financial results for the quarter ended June 30, 2014. ... to the same period of 2013: , Sales grew ... t:slim Pump shipments grew 64 percent to 2,235 pumps from ... 30, 2014 to the same period of 2013: , ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4
... SYK ) reported operating results for the quarter ... Third Quarter Highlights Net sales increased 7.0% ... million Orthopaedic Implants sales increased 1.3% on a constant ... increased 16.3% on a constant currency basis (16.1% as reported) ...
... Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter healthcare ... second quarter and six months ended September 30, 2010, will ... 2010. An earnings conference call will be held the following ... To access the teleconference, please call (877) 718-5108 ...
Cached Medicine Technology:Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results 2
(Date:8/1/2014)... 2014 AAGL, a premiere professional ... is pleased to announce a joint venture with ... and Europe, which strongly recommends every hospital teaching ... endoscopic dry lab for training in an effort ... skills. , Endoscopy is the use of small ...
(Date:8/1/2014)... August 01, 2014 We are ... ES-AMI on AWS Marketplace. EspressReport ES-AMI delivers enterprise ... at $0.50 per hour (AWS infrastructure charges apply). ... easy-to-use enterprise BI and operational reporting system with ... and ad hoc reporting. It allows users to ...
(Date:8/1/2014)... 01, 2014 Get the report here: ... PitchBook presents the 3Q 2014 Private Equity Breakdown report ... investment, exits and fundraising activity in the second quarter ... plan for private equity endeavors for the remainder of ... download it now. , About Merrill DataSite , Merrill ...
(Date:7/31/2014)... Just in time for Washington’s unusually hot ... featuring new summertime drink specials on their famed cocktail ... throughout the season. , A longtime favorite ... Seattle’s best happy hour is well-known for its locally-sourced ... location’s 25th anniversary this summer, Duke is now debuting ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
Breaking Medicine News(10 mins):Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3
... ARBOR, Mich., Dec. 3 A majority of Americans support ... confidence that the cost, quality, value or accessibility of medical ... survey released today by Thomson Reuters. , Sixty percent of ... included in final healthcare reform legislation. Only about one in ...
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Sterilization Technologies: The ... Details the North American sales of capital equipment to ... compound annual growth rate for 2009-2014. , Explains how ...
... , WASHINGTON, Dec. 2 In response to a press ... ," an initiative from the U.S. Anti-Doping Agency (USADA) ... trade association representing the dietary supplement industry, issued the following statement: ... President and CEO: , "We share the concerns of ...
... ... Website traffic rises 8%. According to Coremetrics, a marketing optimization company, ... 2008. , Contrast those statistics to Boston,s Bella Sante Day ... Monday Internet sales rose 59%" - said Tiffany Amorosino, COO of Bella ...
... greater the sleep disturbances, study finds , WEDNESDAY, Dec. 2 ... to increase the risk of sleep apnea, say U.S. researchers. ... drug damages the brain and can cause immediate and dangerous ... of the Johns Hopkins School of Medicine in Baltimore, said ...
... 2 Huntington Memorial Hospital,s stroke program has received ... designating the hospital a primary stroke center. This ... center" hospitals throughout Los Angeles County. , ... more important, a wonderful benefit for Pasadena and its ...
Cached Medicine News:Health News:Thomson Reuters Survey: Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 3Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 5Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 6Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 7Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 8Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 9Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 10Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 11Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 12Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 13Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 2Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 3Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2
... Insulin-like growth factor binding protein-3 (IGFBP-3) is the ... postnatal serum, as a component of the ~150 ... a molecule of IGF-I or IGF-II and ALS, ... actions of the IGFs. The molar concentration of ...
... Growth hormone (GH) is a monomeric protein ... anterior pituitary gland. GH is released from ... pulsatile manner under the regulatory control of ... [1]. The timing and frequency of GH ...
... hormone (GH) is a monomeric protein produced ... pituitary gland. GH is released from the ... manner under the regulatory control of hypothalamic ... The timing and frequency of GH release ...
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
Medicine Products: